Valbenazine is a potent and highly selective vesicular monoamine transporter 2(VMAT2) inhibitor. It is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy. It is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. It significantly improved tardive dyskinesia and was well tolerated in patients. It is an experimental drug being investigated for use in the treatment of tardive dyskinesia and Tourette syndrome. It was developed by Neurocrine Biosciences.